Abstract:Interleukin (IL)-6 is one of the most important survival factors in multiple myeloma (MM), and determines the poor prognosis of MM. IL-6 mainly has a paracrine bone marrow stromal cell origin and an autocrine MM cell origin. As an enzyme having cytoprotective effects, heme oxygenase-1 (HO-1) promotes the growth and drug resistance of various malignant tumors. HO-1 expression levels in bone marrow CD138(+) cells of MM patients were significantly higher than those in healthy donors, and positively correlated with both serum IL-6 and intracellular IL-6 mRNA expression levels. Culture of U266, RPMI8226 and CD138(+) cells with exogenous IL-6 in vitro induced high HO-1 expression levels and allowed them to resist lenalidomide. It is hypothesized that this was probably attributable to IL-6-mediated activation of the Janus kinase 2-signal transducer and activator of transcription 3 pathway. In contrast, without IL-6 coculture, enhanced HO-1 expression in U266, RPMI8226 and bone marrow CD138(+) cells from MM patients significantly inreased IL-6 mRNA expression levels and facilitated autocrine IL-6 production. The findings were associated with high HO-1 expression-enhanced p38 mitogen-activated protein kinase phosphorylation. Reduced HO-1 expression sensitized MM cells to lenalidomide. Therefore, we postulated that IL-6 in the bone marrow microenvironment of MM patients stimulated high HO-1 expression in MM cells and their resistance to lenalidomide. High HO-1 expression also stimulated autocrine IL-6 production, and exacerbated drug resistance and disease. This study supports the use of HO-1 as a possible marker for both MM prognosis and drug resistance, and as a potential therapeutic target.

Antagonistic effect between two IL-6 signal transduction pathways in a human myeloma cell line-U266

Relationship between IL-6 signal transduction pathways and its growth effect on a human myeloma cell line-U266

[Activation of PKA Pathway Inhibits Reactivity of Human Myeloma Cell Line-U266 to IL-6].

The biological function of IL-6 on a human multiple myeloma cell-KM-3 is mediated by Ras/NF-IL-6 signal transduction pathway

IL-6 Inhibits Apoptosis of Human Myeloma Cell Line XG-7 Through Activation of JAK/STAT Pathway and Up-Regulation of Mcl-1.

Interleukin-32 Induce Production of Il-6 in Multiple Myeloma Bone Marrow Stromal Cells

Inhibition of IL-6-induced STAT3 Activation in Myeloma Cells by Protein Kinase A

[Study of IL-6 Signal Transduction Pathway in a Human Multiple Myeloma Cell Line--sko-007].

Interleukin-32 Alpha Promotes The Proliferation Of Multiple Myeloma Cells By Inducing Production Of Il-6 In Bone Marrow Stromal Cells

IL-6 Selectively Activates STAT3 in U937 Cells

The Regulatory Mechanism of IL-6-dependent Proliferation of Human Myeloma Cells

Potential Crosstalk of Interleukin-6-Heme Oxygenase-1 Dependent Mechanism Involved in Resistance to Lenalidomide in Multiple Myeloma Cells

Association and Contribution of Erk to Il-6-Induced Activation of Signal Transducer and Activator of Transcription in A Human Myeloma Cell Line

Stat3 Exerts Two-Way Regulation In The Biological Effects Of Il-6 In M1 Leukemia Cells

Induction of CD45 Expression in a Myeloma Cell Line by IL-6

Synergistic effects of IL-2 and IL-12 on antitumor activity of human PBMC in vitro

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway

Receptor Synergy of Interleukin-6 (IL-6) and Insulin-Like Growth Factor-I in Myeloma Cells That Highly Express IL-6 Receptor Alpha [Corrected].

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.

Comparison of IL-6-activated-nuclear Factors in M1 and 7TD1 Cells

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNα